Polatuzumab Vedotin/R-CHP Meets Primary End Point of Progression-Free Survival for DLBCL in ...

Retrieved on: 2021-08-09 18:00:00

Tags for this article:

Click the tags to see associated articles and topics

Polatuzumab Vedotin/R-CHP Meets Primary End Point of Progression-Free Survival for DLBCL in .... View article details on hiswai:

Excerpt

1: Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated ...

Article found on: www.cancernetwork.com